You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Claims for Patent: 11,306,106

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,306,106

Title:	Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
Abstract:	The present invention provides a pharmaceutical composition containing the following compound having antiviral action: ##STR00001## wherein each of the symbols is defined in the specification.
Inventor(s):	Kawai; Makoto (Osaka, JP)
Assignee:	Shionogi & Co., Ltd. (Osaka, JP)
Application Number:	16/937,877
Patent Claims:	1. A method for treating a disease caused by a virus having cap-dependent endonuclease comprising administering to a patient in need thereof a crystal of the compound of the following formula: ##STR00239## wherein the crystal is selected from the group consisting of: (i) crystal Form I having two or more peaks in diffraction angles (2.theta.) selected from 8.6.+-.0.2.degree., 14.1.+-.0.2.degree., 17.4.+-.0.2.degree., 20.0.+-.0.2.degree., 24.0.+-.0.2.degree., 26.3.+-.0.2.degree., 29.6.+-.0.2.degree. and 35.4.+-.0.2.degree. in an X-ray powder diffraction spectrum, (ii) crystal Form II having two or more peaks in diffraction angles (2.theta.) selected from 4.4.+-.0.2.degree., 8.9.+-.0.2.degree., 11.7.+-.0.2.degree., 14.9.+-.0.2.degree., 22.3.+-.0.2.degree., 24.4.+-.0.2.degree., 28.0.+-.0.2.degree. and 31.5.+-.0.2.degree. in an X-ray powder diffraction spectrum, and (iii) crystal Form III having two or more peaks in diffraction angles (2.theta.) selected from 4.4.+-.0.2.degree., 8.7.+-.0.2.degree., 10.6.+-.0.2.degree., 17.3.+-.0.2.degree., 17.5.+-.0.2.degree., 22.0.+-.0.2.degree., 24.0.+-.0.2.degree., 24.1.+-.0.2.degree. and 31.0.+-.0.2.degree. in an X-ray powder diffraction spectrum. 2. The method according to claim 1, wherein the crystal is (i) crystal Form I having peaks in diffraction angles (2.theta.) of 8.6.+-.0.2.degree., 14.1.+-.0.2.degree., 17.4.+-.0.2.degree., 20.0.+-.0.2.degree., 24.0.+-.0.2.degree., 26.3.+-.0.2.degree., 29.6.+-.0.2.degree. and 35.4.+-.0.2.degree. in an X-ray powder diffraction spectrum. 3. The method according to claim 1, wherein the (i) crystal Form I is administered orally in a single dose. 4. The method according to claim 1, wherein 40 mg or 80 mg of the (i) crystal Form I is administered in a single dose. 5. The method according to claim 1, wherein 5 to 40 mg of the (i) crystal Form I is administered in a single dose depending on the body weight of the patient. 6. The method according to claim 1, wherein 40 mg of the (i) crystal Form I is administered in two tablets of 20 mg per tablet. 7. The method according to claim 1, wherein the (i) crystal Form I is administered and the patient is a human 12 years old or older. 8. The method according to claim 1, wherein the crystal is (ii) crystal Form II having peaks in diffraction angles (2.theta.) of 4.4.+-.0.2.degree., 8.9.+-.0.2.degree., 11.7.+-.0.2.degree., 14.9.+-.0.2.degree., 22.3.+-.0.2.degree., 24.4.+-.0.2.degree., 28.0.+-.0.2.degree. and 31.5.+-.0.2.degree. in an X-ray powder diffraction spectrum. 9. The method according to claim 1, wherein the (ii) crystal Form II is administered orally in a single dose. 10. The method according to claim 1, wherein 40 mg or 80 mg of the (ii) crystal Form II is administered in a single dose. 11. The method according to claim 1, wherein 5 to 40 mg of the (ii) crystal Form II is administered in a single dose depending on the body weight of the patient. 12. The method according to claim 1, wherein 40 mg of the (ii) crystal Form II is administered in two tablets of 20 mg per tablet. 13. The method according to claim 1, wherein the (ii) crystal Form II is administered and the patient is a human 12 years old or older. 14. The method according to claim 1, wherein the crystal is (iii) crystal Form III having peaks in diffraction angles (2.theta.) of 4.4.+-.0.2.degree., 8.7.+-.0.2.degree., 10.6.+-.0.2.degree., 17.3.+-.0.2.degree., 17.5.+-.0.2.degree., 22.0.+-.0.2.degree., 24.0.+-.0.2.degree., 24.1.+-.0.2.degree. and 31.0.+-.0.2.degree. in an X-ray powder diffraction spectrum. 15. The method according to claim 1, wherein the (iii) crystal Form III is administered orally in a single dose. 16. The method according to claim 1, wherein 40 mg or 80 mg of the (iii) crystal Form III is administered in a single dose. 17. The method according to claim 1, wherein 5 to 40 mg of the (iii) crystal Form III is administered in a single dose depending on the body weight of the patient. 18. The method according to claim 1, wherein 40 mg of the (iii) crystal Form III is administered in two tablets of 20 mg per tablet. 19. The method according to claim 1, wherein the (iii) crystal Form III is administered and the patient is a human 12 years old or older. 20. A method for treating influenza comprising administering to a patient in need thereof a crystal of the compound of the following formula: ##STR00240## wherein the crystal is selected from the group consisting of: (i) crystal Form I having two or more peaks in diffraction angles (2.theta.) selected from 8.6.+-.0.2.degree., 14.1.+-.0.2.degree., 17.4.+-.0.2.degree., 20.0.+-.0.2.degree., 24.0.+-.0.2.degree., 26.3.+-.0.2.degree., 29.6.+-.0.2.degree. and 35.4.+-.0.2.degree. in an X-ray powder diffraction spectrum, (ii) crystal Form II having two or more peaks in diffraction angles (2.theta.) selected from 4.4.+-.0.2.degree., 8.9.+-.0.2.degree., 11.7.+-.0.2.degree., 14.9.+-.0.2.degree., 22.3.+-.0.2.degree., 24.4.+-.0.2.degree., 28.0.+-.0.2.degree. and 31.5.+-.0.2.degree. in an X-ray powder diffraction spectrum, and (iii) crystal Form III having two or more peaks in diffraction angles (2.theta.) selected from 4.4.+-.0.2.degree., 8.7.+-.0.2.degree., 10.6.+-.0.2.degree., 17.3.+-.0.2.degree., 17.5.+-.0.2.degree., 22.0.+-.0.2.degree., 24.0.+-.0.2.degree., 24.1.+-.0.2.degree. and 31.0.+-.0.2.degree. in an X-ray powder diffraction spectrum. 21. The method according to claim 20, wherein the crystal is (i) crystal Form I having peaks in diffraction angles (2.theta.) of 8.6.+-.0.2.degree., 14.1.+-.0.2.degree., 17.4.+-.0.2.degree., 20.0.+-.0.2.degree., 24.0.+-.0.2.degree., 26.3.+-.0.2.degree., 29.6.+-.0.2.degree. and 35.4.+-.0.2.degree. in an X-ray powder diffraction spectrum. 22. The method according to claim 20, wherein the (i) crystal Form I is administered orally in a single dose. 23. The method according to claim 20, wherein 40 mg or 80 mg of the (i) crystal Form I is administered in a single dose. 24. The method according to claim 20, wherein 5 to 40 mg of the (i) crystal Form I is administered in a single dose depending on the body weight of the patient. 25. The method according to claim 20, wherein 40 mg of the (i) crystal Form I is administered in two tablets of 20 mg per tablet. 26. The method according to claim 20, wherein the (i) crystal Form I is administered and the patient is a human 12 years old or older. 27. The method according to claim 20, wherein the crystal is (ii) crystal Form II having peaks in diffraction angles (2.theta.) of 4.4.+-.0.2.degree., 8.9.+-.0.2.degree., 11.7.+-.0.2.degree., 14.9.+-.0.2.degree., 22.3.+-.0.2.degree., 24.4.+-.0.2.degree., 28.0.+-.0.2.degree. and 31.5.+-.0.2.degree. in an X-ray powder diffraction spectrum. 28. The method according to claim 20, wherein the (ii) crystal Form II is administered orally in a single dose. 29. The method according to claim 20, wherein 40 mg or 80 mg of the (ii) crystal Form II is administered in a single dose. 30. The method according to claim 20, wherein 5 to 40 mg of the (ii) crystal Form II is administered in a single dose depending on the body weight of the patient. 31. The method according to claim 20, wherein 40 mg of the (ii) crystal Form II is administered in two tablets of 20 mg per tablet. 32. The method according to claim 20, wherein the (ii) crystal Form II is administered and the patient is a human 12 years old or older. 33. The method according to claim 20, wherein the crystal is (iii) crystal Form III having peaks in diffraction angles (2.theta.) of 4.4.+-.0.2.degree., 8.7.+-.0.2.degree., 10.6.+-.0.2.degree., 17.3.+-.0.2.degree., 17.5.+-.0.2.degree., 22.0.+-.0.2.degree., 24.0.+-.0.2.degree., 24.1.+-.0.2.degree. and 31.0.+-.0.2.degree. in an X-ray powder diffraction spectrum. 34. The method according to claim 20, wherein the (iii) crystal Form III is administered orally in a single dose. 35. The method according to claim 20, wherein 40 mg or 80 mg of the (iii) crystal Form III is administered in a single dose. 36. The method according to claim 20, wherein 5 to 40 mg of the (iii) crystal Form III is administered in a single dose depending on the body weight of the patient. 37. The method according to claim 20, wherein 40 mg of the (iii) crystal Form III is administered in two tablets of 20 mg per tablet. 38. The method according to claim 20, wherein the (iii) crystal Form III is administered and the patient is a human 12 years old or older. 39. A method for preventing influenza comprising administering to a patient in need thereof a crystal of the compound of the following formula: ##STR00241## wherein the crystal is selected from the group consisting of: (i) crystal Form I having two or more peaks in diffraction angles (2.theta.) selected from 8.6.+-.0.2.degree., 14.1.+-.0.2.degree., 17.4.+-.0.2.degree., 20.0.+-.0.2.degree., 24.0.+-.0.2.degree., 26.3.+-.0.2.degree., 29.6.+-.0.2.degree. and 35.4.+-.0.2.degree. in an X-ray powder diffraction spectrum, (ii) crystal Form II having two or more peaks in diffraction angles (2.theta.) selected from 4.4.+-.0.2.degree., 8.9.+-.0.2.degree., 11.7.+-.0.2.degree., 14.9.+-.0.2.degree., 22.3.+-.0.2.degree., 24.4.+-.0.2.degree., 28.0.+-.0.2.degree. and 31.5.+-.0.2.degree. in an X-ray powder diffraction spectrum, and (iii) crystal Form III having two or more peaks in diffraction angles (2.theta.) selected from 4.4.+-.0.2.degree., 8.7.+-.0.2.degree., 10.6.+-.0.2.degree., 17.3.+-.0.2.degree., 17.5.+-.0.2.degree., 22.0.+-.0.2.degree., 24.0.+-.0.2.degree., 24.1.+-.0.2.degree. and 31.0.+-.0.2.degree. in an X-ray powder diffraction spectrum. 40. The method according to claim 39, wherein the crystal is (i) crystal Form I having peaks in diffraction angles (2.theta.) of 8.6.+-.0.2.degree., 14.1.+-.0.2.degree., 17.4.+-.0.2.degree., 20.0.+-.0.2.degree., 24.0.+-.0.2.degree., 26.3.+-.0.2.degree., 29.6.+-.0.2.degree. and 35.4.+-.0.2.degree. in an X-ray powder diffraction spectrum. 41. The method according to claim 39, wherein the (i) crystal Form I is administered orally in a single dose. 42. The method according to claim 39, wherein 40 mg or 80 mg of the (i) crystal Form I is administered in a single dose. 43. The method according to claim 39, wherein 5 to 40 mg of the (i) crystal Form I is administered in a single dose depending on the body weight of the patient. 44. The method according to claim 39, wherein 40 mg of the (i) crystal Form I is administered in two tablets of 20 mg per tablet. 45. The method according to claim 39, wherein the (i) crystal Form I is administered and the patient is a human 12 years old or older. 46. The method according to claim 39, wherein the crystal is (ii) crystal Form II having peaks in diffraction angles (2.theta.) of 4.4.+-.0.2.degree., 8.9.+-.0.2.degree., 11.7.+-.0.2.degree., 14.9.+-.0.2.degree., 22.3.+-.0.2.degree., 24.4.+-.0.2.degree., 28.0.+-.0.2.degree. and 31.5.+-.0.2.degree. in an X-ray powder diffraction spectrum. 47. The method according to claim 39, wherein the (ii) crystal Form II is administered orally in a single dose. 48. The method according to claim 39, wherein 40 mg or 80 mg of the (ii) crystal Form II is administered in a single dose. 49. The method according to claim 39, wherein 5 to 40 mg of the (ii) crystal Form II is administered in a single dose depending on the body weight of the patient. 50. The method according to claim 39, wherein 40 mg of the (ii) crystal Form II is administered in two tablets of 20 mg per tablet. 51. The method according to claim 39, wherein the (ii) crystal Form II is administered and the patient is a human 12 years old or older. 52. The method according to claim 39, wherein the crystal is (iii) crystal Form III having peaks in diffraction angles (2.theta.) of 4.4.+-.0.2.degree., 8.7.+-.0.2.degree., 10.6.+-.0.2.degree., 17.3.+-.0.2.degree., 17.5.+-.0.2.degree., 22.0.+-.0.2.degree., 24.0.+-.0.2.degree., 24.1.+-.0.2.degree. and 31.0.+-.0.2.degree. in an X-ray powder diffraction spectrum. 53. The method according to claim 39, wherein the (iii) crystal Form III is administered orally in a single dose. 54. The method according to claim 39, wherein 40 mg or 80 mg of the (iii) crystal Form III is administered in a single dose. 55. The method according to claim 39, wherein 5 to 40 mg of the (iii) crystal Form III is administered in a single dose depending on the body weight of the patient. 56. The method according to claim 39, wherein 40 mg of the (iii) crystal Form III is administered in two tablets of 20 mg per tablet. 57. The method according to claim 39, wherein the (iii) crystal Form III is administered and the patient is a human 12 years old or older.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.